Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;26(3):366-71.
doi: 10.1111/jon.12320. Epub 2015 Dec 26.

Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas

Affiliations

Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas

Julio Arevalo-Perez et al. J Neuroimaging. 2016 May.

Abstract

Background and purpose: Low-grade and anaplastic oligodendrogliomas are often difficult to differentiate on the basis of conventional MR imaging characteristics. Dynamic contrast-enhanced (DCE) MRI can assess tumor microvasculature and has demonstrated utility for predicting glioma grade and prognosis in primary brain tumors. The aim of our study was to evaluate the performance of plasma volume (Vp) and volume transfer coefficient (K(trans) ) derived from DCE MRI in differentiating between grade II and grade III oligodendrogliomas.

Materials and methods: Twenty-four consecutive patients with pathologically confirmed oligodendroglioma (World Health Organization grade II, n = 14 and grade III, n = 10) were retrospectively assessed. Pretreatment DCE MRI was performed and regions of interest were manually drawn around the entire tumor volume to calculate Vp and K(trans) . The Mann-Whitney U test and receiver operating characteristic (ROC) analysis were performed to compare pharmacokinetic parameters between the 2 groups.

Results: The Vpmean values for grade III oligodendrogliomas were significantly higher (P = .03) than those for grade II oligodendrogliomas. The K(trans) mean values were higher in grade III lesions, but the difference between the 2 groups was not statistically significant (P > .05). Based on ROC analysis, the Vpmean (area under curve = .757, SD = .1) cut-off value that provided the best combination of high sensitivity and specificity to distinguish between grade II and III oligodendrogliomas was 2.35 (P < .03).

Conclusion: The results of our study suggest the DCE MRI parameter Vpmean can noninvasively differentiate between grade II and grade III oligodendrogliomas.

Keywords: DCE; MRI; Oligodendrogliomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box plot illustrating the mean values and standard deviations for Vp of grade II and grade III oligodendrogliomas.
Figure 2
Figure 2
Axial T1-weighted post contrast images with corresponding Vp and Ktrans perfusion color maps of grade II (top row) and grade III (bottom row) oligodendrogliomas. Both lesions demonstrate mild enhancement (arrows), but the grade III lesion demonstrates greater Vp than the grade II lesion. The Ktrans is also higher in the grade III lesion but the difference is less striking.
Figure 3
Figure 3
Receiver operating characteristic (ROC) curves depicting the true positive rate (specificity) and the false positive rate (sensitivity) of DCE-MRI pharmacokinetic parameters Vp and Ktrans in differentiating grade II versus grade III oligodendrogliomas.

References

    1. Chawla S, Krejza J, Vossough A, et al. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol. 2013;34:1542–9. - PMC - PubMed
    1. Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist. 2009;14:155–63. - PubMed
    1. Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother. 2015;15:601–20. - PubMed
    1. Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014;19:403–13. - PMC - PubMed
    1. Field M, Witham TF, Flickinger JC, Kondziolka D, Lunsford LD. Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. J Neurosurg. 2001;94:545–51. - PubMed

MeSH terms

LinkOut - more resources